Drug interactions
Deferasirox + Metformin-repaglinide
Severity: Major
Deferasirox and Metformin-repaglinide: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Deferasirox inhibits CYP2C8 and can substantially raise repaglinide exposure, which increases the risk of hypoglycemia. Repaglinide is a sensitive CYP2C8 substrate, and the combination has been studied pharmacokinetically.
What this interaction means in plain words
Deferasirox and Metformin-repaglinide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Deferasirox belongs to Miscellaneous; Metformin-repaglinide belongs to Endocrine.
Why it happens
Inhibition of CYP2C8 (and to a lesser extent CYP3A4) metabolism of repaglinide.
What to do
Avoid the combination if possible; otherwise reduce the repaglinide dose and monitor blood glucose closely.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Deferasirox and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Deferasirox
Frequently asked questions
Can I take Deferasirox with Metformin-repaglinide?
MediHelp rates the interaction as major. Deferasirox and Metformin-repaglinide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Deferasirox inhibits CYP2C8 and can substantially raise repaglinide exposure, which increases the risk of hypoglycemia. Repaglinide is a sensitive CYP2C8 substrate, and the combination has been studied pharmacokinetically.
How serious is the interaction between Deferasirox and Metformin-repaglinide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible; otherwise reduce the repaglinide dose and monitor blood glucose closely.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
